# Minimally invasive surgery in neurogenic tumours

## TL;DR

Minimally invasive surgery for neurogenic tumors is becoming more common, offering benefits like faster recovery but requiring careful evaluation of risks and proper guidelines.

## Contribution

The paper provides structured guidelines for MIS in pediatric neurogenic tumors to ensure safe and effective use.

## Key findings

- MIS has evolved from a diagnostic tool to a therapeutic option in selected cases.
- Technical challenges include limited space and loss of tactile feedback.
- Guidelines are proposed to help surgeons adopt MIS safely while preserving oncologic outcomes.

## Abstract

The use of minimally invasive surgery (MIS) for the diagnosis and treatment of neurogenic tumours has markedly increased over the past decade, evolving from a diagnostic and staging tool to a therapeutic option in carefully selected cases. The advantages of MIS—reduced postoperative pain, shorter hospital stay, and faster recovery—must be weighed against its technical challenges, including limited operative space, loss of tactile feedback and increased risk when image-defined risk factors are present. This chapter reviews current evidence, outlines practical indications and contraindications and proposes structured guidelines for MIS in paediatric neurogenic tumours to assist surgeons in safe adoption while maintaining oncologic integrity.